Search results

7513 results

Sorted by Date . Sort by Relevance

  1. Preventing type 2 diabetes

    Everything NICE has said on preventing type 2 diabetes in an interactive flowchart

  2. Board committees

    Audit and risk committee The audit and risk committee provides an independent, objective review of arrangements for internal control within NICE. The

  3. Hypertension in pregnancy

    Everything NICE has said on diagnosing and managing hypertension in pregnancy in an interactive flowchart

  4. Coronavirus (COVID-19)

    We're supporting the NHS and social care to respond quickly to the challenges of the coronavirus pandemic. We've brought together information that may help you.

  5. Planning our rapid COVID-19 response

    NICE is supporting the NHS in its response to managing the COVID-19 pandemic by producing rapid guidelines and rapid evidence summaries. Find out what topics we're currently looking at.

  6. Diagnostics guidance static list

    The following published diagnostics assessments have been transferred to the static list. Guidance is moved to the static list following consultation

  7. EBSCO

    Provider name: EBSCO Lot details Lot 1 - Databases, Aggregated Evidence Resource Summaries, Point of Care (PoC) Tools Lot 2 - Electronic

  8. Endorsement

    Formally endorses resources produced by external organisations that support the implementation of NICE guidance and the use of quality standards.

  9. COVID-19 rapid guideline: dialysis service delivery (NG160)

    The purpose of this guideline is to maximise the safety of patients on dialysis, while protecting staff from infection. It will also enable dialysis services to make the best use of NHS resources and match the capacity of dialysis services to patient needs if these become limited because of the COVID-19 pandemic.

  10. COVID-19 rapid guideline: rheumatological autoimmune, inflammatory and metabolic bone disorders (NG167)

    The purpose of this guideline is to maximise the safety of children and adults with rheumatological autoimmune, inflammatory and metabolic bone disorders during the COVID-19 pandemic, while protecting staff from infection. It also enables services to make the best use of NHS resources.

  11. Public health advisory committees

    Public health advisory committees (PHACs) are the standing committees responsible for the development of our public health guidance. Each committee...

  12. COVID-19 rapid guideline: children and young people who are immunocompromised (NG174)

    The purpose of this guideline is to maximise the safety of children and young people who are immunocompromised during the COVID-19 pandemic. It also aims to protect staff from infection and enable services to make the best use of NHS resources.

  13. Changes to how we work

    Find out about how NICE has changed its methods of producing guidance during the coronavirus pandemic.

  14. Jobs

    Jobs at NICE. Includes current vacancies, roles, location and salary information.

  15. Heavy menstrual bleeding

    Everything NICE has said on assessing and managing heavy menstrual bleeding in an interactive flowchart

  16. Sunlight exposure: risks and benefits

    Everything NICE has said on how to communicate the risks and benefits of natural sunlight exposure in an interactive flowchart

  17. Committee B members

    Find out more about the NICE technology appraisal advisory committee B members and their registered interests

  18. Scholars

    Scholarships are one year opportunities to improve quality of care and contribute to your professional development

  19. STA timeline

    A step-by-step timeline of the process we used to develop single technology appraisals (STA)

  20. MTA process timeline

    These are the main stages in multiple technology appraisals process. Timings are approximate. For a full description of the appraisal process see our

  21. NICE Evidence Services issues

    The information below provides a summary of known issues and upcoming changes related to NICE Evidence Services. This information will be updated...

  22. COVID-19 rapid guideline: chronic kidney disease (NG176)

    The purpose of this guideline is to maximise the safety of adults with chronic kidney disease during the COVID-19 pandemic. It also aims to protect staff from infection and enable services to make the best use of NHS resources.

  23. COVID-19 rapid guideline: interstitial lung disease (NG177)

    The purpose of this guideline is to maximise the safety of adults with interstitial lung disease, including idiopathic pulmonary fibrosis and pulmonary sarcoidosis, during the COVID-19 pandemic. It also aims to protect staff from infection and enable services to make the best use of NHS resources.

  24. Scientific advice

    Advice from NICE to help you generate evidence to inform future NICE evaluations and to enable market access

  25. Lorlatinib for previously treated ALK-positive advanced non-small-cell lung cancer (TA628)

    Evidence-based recommendations on lorlatinib (Lorviqua) for previously treated ALK-positive advanced non-small-cell lung cancer in adults

  26. Obinutuzumab with bendamustine for treating follicular lymphoma after rituximab (TA629)

    Evidence-based recommendations on obinutuzumab (Gazyvaro) with bendamustine for follicular lymphoma that has not responded or has progressed up to 6 months

  27. Brand guidelines

    This is an overview of the NICE brand identity incorporating who we are, what we do, and the values underpinning our work. Who we are NICE is the...

  28. Non-Hodgkin's lymphoma

    Everything NICE has said on diagnosing and managing non-Hodgkin's lymphoma in adults and young people 16 years and older in an interactive flowchart

  29. Diagnostics advisory committee

    Our diagnostics assessment recommendations are prepared by an independent advisory committee called the diagnostics advisory committee (DAC). Standing